(ITGR) Integer Holdings - Overview
Sector: HealthcareIndustry: Medical Devices | Exchange NYSE (USA) | Currency USD | Market Cap: 2.990m | Total Return -27.7% in 12m
Stock: Medical Devices, Components, Batteries, Leads
Total Rating 47
Risk 81
Buy Signal -0.67
| Risk 5d forecast | |
|---|---|
| Volatility | 28.5% |
| Relative Tail Risk | -8.18% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.59 |
| Alpha | -35.90 |
| Character TTM | |
|---|---|
| Beta | 0.459 |
| Beta Downside | 0.833 |
| Drawdowns 3y | |
|---|---|
| Max DD | 56.14% |
| CAGR/Max DD | 0.06 |
EPS (Earnings per Share)
Revenue
Description: ITGR Integer Holdings March 05, 2026
Integer Holdings Corporation (ITGR) is a medical device contract development and manufacturing organization (CDMO). This business model involves designing, developing, and manufacturing medical devices for other companies, primarily multi-national original equipment manufacturers (OEMs).
The companys product portfolio is extensive, covering various medical specialties. These include interventional cardiology, structural heart, and peripheral vascular devices, as well as cardiac rhythm management products like pacemakers and defibrillators. ITGR also produces neuromodulation devices and components such as batteries and device enclosures. The healthcare equipment sector is characterized by stringent regulatory requirements and a focus on innovation.
ITGR operates globally, with facilities in the United States, Costa Rica, Puerto Rico, and Ireland. The company serves markets including cardiac rhythm management, neuromodulation, orthopedics, and advanced surgical. For a deeper dive into ITGRs market position and financial health, consider exploring its profile on ValueRay.
Headlines to watch out for
- Medical device demand drives revenue growth
- Regulatory approvals impact product launch timelines
- Raw material costs influence manufacturing margins
- Healthcare spending trends affect device adoption
- OEM customer relationships secure long-term contracts
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income: 102.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA 1.14 > 1.0 |
| NWC/Revenue: 29.03% < 20% (prev 25.86%; Δ 3.17% < -1%) |
| CFO/TA 0.06 > 3% & CFO 196.1m > Net Income 102.8m |
| Net Debt (1.38b) to EBITDA (362.3m): 3.82 < 3 |
| Current Ratio: 3.32 > 1.5 & < 3 |
| Outstanding Shares: last quarter (35.1m) vs 12m ago -3.03% < -2% |
| Gross Margin: 27.09% > 18% (prev 0.27%; Δ 2.68k% > 0.5%) |
| Asset Turnover: 57.14% > 50% (prev 55.77%; Δ 1.37% > 0%) |
| Interest Coverage Ratio: 5.36 > 6 (EBITDA TTM 362.3m / Interest Expense TTM 43.2m) |
Altman Z'' 3.13
| A: 0.16 (Total Current Assets 770.1m - Total Current Liabilities 232.0m) / Total Assets 3.41b |
| B: 0.29 (Retained Earnings 994.1m / Total Assets 3.41b) |
| C: 0.07 (EBIT TTM 231.6m / Avg Total Assets 3.24b) |
| D: 0.63 (Book Value of Equity 1.05b / Total Liabilities 1.66b) |
| Altman-Z'' Score: 3.13 = A |
Beneish M -3.09
| DSRI: 0.92 (Receivables 346.1m/349.0m, Revenue 1.85b/1.72b) |
| GMI: 0.99 (GM 27.09% / 26.83%) |
| AQI: 0.97 (AQ_t 0.58 / AQ_t-1 0.59) |
| SGI: 1.08 (Revenue 1.85b / 1.72b) |
| TATA: -0.03 (NI 102.8m - CFO 196.1m) / TA 3.41b) |
| Beneish M-Score: -3.09 (Cap -4..+1) = AA |
What is the price of ITGR shares?
As of March 30, 2026, the stock is trading at USD 85.33 with a total of 343,292 shares traded.
Over the past week, the price has changed by +0.00%, over one month by -1.56%, over three months by +8.66% and over the past year by -27.69%.
Over the past week, the price has changed by +0.00%, over one month by -1.56%, over three months by +8.66% and over the past year by -27.69%.
Is ITGR a buy, sell or hold?
Integer Holdings has received a consensus analysts rating of 4.60.
Therefore, it is recommended to buy ITGR.
- StrongBuy: 7
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ITGR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 93.3 | 9.3% |
| Analysts Target Price | 93.3 | 9.3% |
ITGR Fundamental Data Overview March 29, 2026
P/E Trailing = 29.526
P/E Forward = 16.6945
P/S = 1.613
P/B = 1.6809
P/EG = 1.3902
Revenue TTM = 1.85b USD
EBIT TTM = 231.6m USD
EBITDA TTM = 362.3m USD
Long Term Debt = 1.19b USD (from longTermDebt, last quarter)
Short Term Debt = 22.1m USD (from shortTermDebt, last quarter)
Debt = 1.40b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.38b USD (from netDebt column, last quarter)
Enterprise Value = 4.37b USD (2.99b + Debt 1.40b - CCE 17.2m)
Interest Coverage Ratio = 5.36 (Ebit TTM 231.6m / Interest Expense TTM 43.2m)
EV/FCF = 29.28x (Enterprise Value 4.37b / FCF TTM 149.3m)
FCF Yield = 3.42% (FCF TTM 149.3m / Enterprise Value 4.37b)
FCF Margin = 8.06% (FCF TTM 149.3m / Revenue TTM 1.85b)
Net Margin = 5.55% (Net Income TTM 102.8m / Revenue TTM 1.85b)
Gross Margin = 27.09% ((Revenue TTM 1.85b - Cost of Revenue TTM 1.35b) / Revenue TTM)
Gross Margin QoQ = 26.43% (prev 26.98%)
Tobins Q-Ratio = 1.28 (Enterprise Value 4.37b / Total Assets 3.41b)
Interest Expense / Debt = 0.72% (Interest Expense 10.1m / Debt 1.40b)
Taxrate = 18.00% (22.6m / 125.4m)
NOPAT = 190.0m (EBIT 231.6m * (1 - 18.00%))
Current Ratio = 3.32 (Total Current Assets 770.1m / Total Current Liabilities 232.0m)
Debt / Equity = 0.80 (Debt 1.40b / totalStockholderEquity, last quarter 1.75b)
Debt / EBITDA = 3.82 (Net Debt 1.38b / EBITDA 362.3m)
Debt / FCF = 9.26 (Net Debt 1.38b / FCF TTM 149.3m)
Total Stockholder Equity = 1.70b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.17% (Net Income 102.8m / Total Assets 3.41b)
RoE = 6.05% (Net Income TTM 102.8m / Total Stockholder Equity 1.70b)
RoCE = 8.03% (EBIT 231.6m / Capital Employed (Equity 1.70b + L.T.Debt 1.19b))
RoIC = 6.54% (NOPAT 190.0m / Invested Capital 2.90b)
WACC = 5.37% (E(2.99b)/V(4.39b) * Re(7.60%) + D(1.40b)/V(4.39b) * Rd(0.72%) * (1-Tc(0.18)))
Discount Rate = 7.60% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares Correlation 3-Years: 81.65 | Cagr: 2.90%
[DCF] Terminal Value 88.44% ; FCFF base≈129.4m ; Y1≈159.7m ; Y5≈272.4m
[DCF] Fair Price = 189.5 (EV 7.90b - Net Debt 1.38b = Equity 6.52b / Shares 34.4m; r=6.0% [WACC]; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 90.87 | EPS CAGR: 24.24% | SUE: 1.42 | # QB: 2
Revenue Correlation: 96.33 | Revenue CAGR: 11.78% | SUE: 0.62 | # QB: 0
EPS next Quarter (2026-06-30): EPS=1.54 | Chg7d=-0.001 | Chg30d=+0.014 | Revisions Net=+2 | Analysts=8
EPS current Year (2026-12-31): EPS=6.49 | Chg7d=+0.014 | Chg30d=+0.195 | Revisions Net=+9 | Growth EPS=+1.4% | Growth Revenue=-0.3%
EPS next Year (2027-12-31): EPS=7.23 | Chg7d=+0.003 | Chg30d=+0.371 | Revisions Net=+6 | Growth EPS=+11.3% | Growth Revenue=+6.5%
[Analyst] Revisions Ratio: +0.33 (4 Up / 2 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 4.5% (Discount Rate 7.9% - Earnings Yield 3.4%)
[Growth] Growth Spread = -7.7% (Analyst -3.2% - Implied 4.5%)
P/E Forward = 16.6945
P/S = 1.613
P/B = 1.6809
P/EG = 1.3902
Revenue TTM = 1.85b USD
EBIT TTM = 231.6m USD
EBITDA TTM = 362.3m USD
Long Term Debt = 1.19b USD (from longTermDebt, last quarter)
Short Term Debt = 22.1m USD (from shortTermDebt, last quarter)
Debt = 1.40b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.38b USD (from netDebt column, last quarter)
Enterprise Value = 4.37b USD (2.99b + Debt 1.40b - CCE 17.2m)
Interest Coverage Ratio = 5.36 (Ebit TTM 231.6m / Interest Expense TTM 43.2m)
EV/FCF = 29.28x (Enterprise Value 4.37b / FCF TTM 149.3m)
FCF Yield = 3.42% (FCF TTM 149.3m / Enterprise Value 4.37b)
FCF Margin = 8.06% (FCF TTM 149.3m / Revenue TTM 1.85b)
Net Margin = 5.55% (Net Income TTM 102.8m / Revenue TTM 1.85b)
Gross Margin = 27.09% ((Revenue TTM 1.85b - Cost of Revenue TTM 1.35b) / Revenue TTM)
Gross Margin QoQ = 26.43% (prev 26.98%)
Tobins Q-Ratio = 1.28 (Enterprise Value 4.37b / Total Assets 3.41b)
Interest Expense / Debt = 0.72% (Interest Expense 10.1m / Debt 1.40b)
Taxrate = 18.00% (22.6m / 125.4m)
NOPAT = 190.0m (EBIT 231.6m * (1 - 18.00%))
Current Ratio = 3.32 (Total Current Assets 770.1m / Total Current Liabilities 232.0m)
Debt / Equity = 0.80 (Debt 1.40b / totalStockholderEquity, last quarter 1.75b)
Debt / EBITDA = 3.82 (Net Debt 1.38b / EBITDA 362.3m)
Debt / FCF = 9.26 (Net Debt 1.38b / FCF TTM 149.3m)
Total Stockholder Equity = 1.70b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.17% (Net Income 102.8m / Total Assets 3.41b)
RoE = 6.05% (Net Income TTM 102.8m / Total Stockholder Equity 1.70b)
RoCE = 8.03% (EBIT 231.6m / Capital Employed (Equity 1.70b + L.T.Debt 1.19b))
RoIC = 6.54% (NOPAT 190.0m / Invested Capital 2.90b)
WACC = 5.37% (E(2.99b)/V(4.39b) * Re(7.60%) + D(1.40b)/V(4.39b) * Rd(0.72%) * (1-Tc(0.18)))
Discount Rate = 7.60% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares Correlation 3-Years: 81.65 | Cagr: 2.90%
[DCF] Terminal Value 88.44% ; FCFF base≈129.4m ; Y1≈159.7m ; Y5≈272.4m
[DCF] Fair Price = 189.5 (EV 7.90b - Net Debt 1.38b = Equity 6.52b / Shares 34.4m; r=6.0% [WACC]; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 90.87 | EPS CAGR: 24.24% | SUE: 1.42 | # QB: 2
Revenue Correlation: 96.33 | Revenue CAGR: 11.78% | SUE: 0.62 | # QB: 0
EPS next Quarter (2026-06-30): EPS=1.54 | Chg7d=-0.001 | Chg30d=+0.014 | Revisions Net=+2 | Analysts=8
EPS current Year (2026-12-31): EPS=6.49 | Chg7d=+0.014 | Chg30d=+0.195 | Revisions Net=+9 | Growth EPS=+1.4% | Growth Revenue=-0.3%
EPS next Year (2027-12-31): EPS=7.23 | Chg7d=+0.003 | Chg30d=+0.371 | Revisions Net=+6 | Growth EPS=+11.3% | Growth Revenue=+6.5%
[Analyst] Revisions Ratio: +0.33 (4 Up / 2 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 4.5% (Discount Rate 7.9% - Earnings Yield 3.4%)
[Growth] Growth Spread = -7.7% (Analyst -3.2% - Implied 4.5%)